cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.4xyz4q
title: Occurrence Download

description: A dataset listing the 263 species recorded in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Human Observation",
 "Country is India",
 "DatasetKey is EOD – eBird Observation Dataset",
 "Geometry POLYGON((77.76652 13.05744,77.76821 13.05518,77.77836 13.05744,77.77836 13.09207,77.76455 13.10043,77.76117 13.0963,77.75829 13.08435,77.75827 13.07572,77.76652 13.05744))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset's 263 records were derived from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002494-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.9zf5fc
title: Occurrence Download

description: A dataset containing 3759 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Coptotomus Say, 1830"
 ]
}

 The dataset includes 3759 records from 49 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012572-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mrasz3
title: Occurrence Download

description: A dataset containing 174897 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Harmonised freshwater fish occurrence and abundance data for 12 federal states in Germany"
 ]
}

 The dataset includes 174897 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002492-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.uj44nc
title: Occurrence Download

description: A dataset containing 84 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is India",
 "TaxonKey is Trachemys scripta elegans (Wied, 1838)"
 ]
}

 The dataset includes 84 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002520-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.4z5543
title: Occurrence Download

description: A dataset containing 59 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Cupressus chengiana S.Y.Hu"
 ]
}

 The dataset includes 59 records from 12 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0027546-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14720401
title: The Secret Diary of K. B. Hase – 1825 (xml)

description: This is the xml dataset for the  online edition of year 1825 of Karl Benedikt Hase’s ‘secret’ diary, which he kept in a form of Ancient Greek during his life as a scholar in 19th-century Paris.

The diary is being edited and studied as part of the LAGOOS (ΛΑΓΩΌΣ) project, funded by the Austrian Science Fund (FWF, Grant DOI 10.55776/Y1519) and hosted by the University of Innsbruck.

Hase’s Greek diaries have been prepared for this online edition by the LAGOOS project team as a collaborative effort.During the team’s daily work, the following areas of responsibility have been assigned:

General editor: William M. Barton

Transcription: Lev Shadrin

Regesta: Mariia Hrynevych

Tagged Entities: Chiara Telesca
DOI: 10.5281/zenodo.14724735
title: The Secret Diary of K. B. Hase – 1825 (xml)

description: This is the xml dataset for the  online edition of year 1825 of Karl Benedikt Hase’s ‘secret’ diary, which he kept in a form of Ancient Greek during his life as a scholar in 19th-century Paris.

The diary is being edited and studied as part of the LAGOOS (ΛΑΓΩΌΣ) project, funded by the Austrian Science Fund (FWF, Grant DOI 10.55776/Y1519) and hosted by the University of Innsbruck.

Hase’s Greek diaries have been prepared for this online edition by the LAGOOS project team as a collaborative effort.During the team’s daily work, the following areas of responsibility have been assigned:

General editor: William M. Barton

Transcription: Lev Shadrin

Regesta: Mariia Hrynevych

Tagged Entities: Chiara Telesca
DOI: 10.5281/zenodo.11927728
title: RSL

description: This spreadsheet compiles and categorises information from a scoping review of 102 studies analysing the use of Minecraft in educational contexts. It includes details such as authors, study titles, keywords, years of publication, publication titles, quality levels, journal countries, subject areas, educational contexts, pedagogical theories applied, and game mechanics used, providing a comprehensive overview of how Minecraft is used as an educational tool in different settings and disciplines. Additional sheets provide details on the search methodology employed.
DOI: 10.15468/dl.hvutc3
title: Occurrence Download

description: A dataset containing 289786 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Smilax L.)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 289786 records from 1310 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002500-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.sraxar
title: Occurrence Download

description: A dataset containing 2031 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Soehrensia Backeb.)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 2031 records from 36 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002521-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.48544/db6a88a3-1952-427e-9aba-469e3ba61cd9
title: Toolbox Virtual Reality als didactisch instrument
DOI: 10.15468/dl.rtsbsc
title: Occurrence Download

description: A dataset containing 5501 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Lopinga achine (Scopoli, 1763)",
 "Year 1991-2010"
 ]
}

 The dataset includes 5501 records from 103 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002522-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.5scvx8
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Copiapoa armata (F.Ritter) Helmut Walter & Larridon"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002523-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28181405.v1
title: Supplementary Material for: Fibroblast growth factor 23, endogenous erythropoietin, erythropoiesis-stimulating agents, and erythropoietin resistance in hemodialysis patients

description: Introduction. Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO has been shown to stimulate FGF23 production. However, little is known about the relationships between FGF23, erythropoiesis-stimulating agent (ESA) treatment, ESA resistance, and endogenous EPO in hemodialysis patients.
Methods. We analyzed cross-sectional data from a cohort of 654 maintenance hemodialysis patients. We examined the associations of intact or C-terminal FGF23 with ESA treatment, ESA resistance index (ERI), hemoglobin, C-reactive protein, and endogenous EPO levels using linear regression models. EPO was measured only in patients not receiving ESAs.
Results. A total of 458 patients (70%) were treated with ESAs. The median EPO concentration in non-ESA users was 7.8 (interquartile range, 5.3-14.4) mIU/mL. The median levels of intact and C-terminal FGF23 were 1598 (interquartile range, 548-4586) pg/mL and 38.7 (interquartile range, 14.0-127.6) pmol/L, respectively, in non-ESA users and 1955 (interquartile range, 573-5264) pg/mL and 41.4 (interquartile range, 13.9-116.8) pmol/L, respectively, in ESA users. After adjustment for potential confounders, higher ESA dose was associated with higher FGF23 levels measured by both intact and C-terminal assays. Higher C-terminal FGF23 was also associated with higher ERI, lower hemoglobin, and higher endogenous EPO, but no such associations were observed for intact FGF23 levels.
Conclusions. Both intact and C-terminal FGF23 showed similar associations with ESA dose, but they showed different patterns of association with other parameters related to anemia. Further research is needed to elucidate the mechanisms underlying these different associations.
DOI: 10.15468/dl.hw5jtq
title: Occurrence Download

description: A dataset containing 360 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Bee species data, InsectScale 2008"
 ]
}

 The dataset includes 360 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002524-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28181405.v2
title: Supplementary Material for: Fibroblast growth factor 23, endogenous erythropoietin, erythropoiesis-stimulating agents, and erythropoietin resistance in hemodialysis patients

description: Introduction. Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO has been shown to stimulate FGF23 production. However, little is known about the relationships between FGF23, erythropoiesis-stimulating agent (ESA) treatment, ESA resistance, and endogenous EPO in hemodialysis patients.
Methods. We analyzed cross-sectional data from a cohort of 654 maintenance hemodialysis patients. We examined the associations of intact or C-terminal FGF23 with ESA treatment, ESA resistance index (ERI), hemoglobin, C-reactive protein, and endogenous EPO levels using linear regression models. EPO was measured only in patients not receiving ESAs.
Results. A total of 458 patients (70%) were treated with ESAs. The median EPO concentration in non-ESA users was 7.8 (interquartile range, 5.3-14.4) mIU/mL. The median levels of intact and C-terminal FGF23 were 1598 (interquartile range, 548-4586) pg/mL and 38.7 (interquartile range, 14.0-127.6) pmol/L, respectively, in non-ESA users and 1955 (interquartile range, 573-5264) pg/mL and 41.4 (interquartile range, 13.9-116.8) pmol/L, respectively, in ESA users. After adjustment for potential confounders, higher ESA dose was associated with higher FGF23 levels measured by both intact and C-terminal assays. Higher C-terminal FGF23 was also associated with higher ERI, lower hemoglobin, and higher endogenous EPO, but no such associations were observed for intact FGF23 levels.
Conclusions. Both intact and C-terminal FGF23 showed similar associations with ESA dose, but they showed different patterns of association with other parameters related to anemia. Further research is needed to elucidate the mechanisms underlying these different associations.
DOI: 10.6084/m9.figshare.28181405.v3
title: Supplementary Material for: Fibroblast growth factor 23, endogenous erythropoietin, erythropoiesis-stimulating agents, and erythropoietin resistance in hemodialysis patients

description: Introduction. Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO has been shown to stimulate FGF23 production. However, little is known about the relationships between FGF23, erythropoiesis-stimulating agent (ESA) treatment, ESA resistance, and endogenous EPO in hemodialysis patients.
Methods. We analyzed cross-sectional data from a cohort of 654 maintenance hemodialysis patients. We examined the associations of intact or C-terminal FGF23 with ESA treatment, ESA resistance index (ERI), hemoglobin, C-reactive protein, and endogenous EPO levels using linear regression models. EPO was measured only in patients not receiving ESAs.
Results. A total of 458 patients (70%) were treated with ESAs. The median EPO concentration in non-ESA users was 7.8 (interquartile range, 5.3-14.4) mIU/mL. The median levels of intact and C-terminal FGF23 were 1598 (interquartile range, 548-4586) pg/mL and 38.7 (interquartile range, 14.0-127.6) pmol/L, respectively, in non-ESA users and 1955 (interquartile range, 573-5264) pg/mL and 41.4 (interquartile range, 13.9-116.8) pmol/L, respectively, in ESA users. After adjustment for potential confounders, higher ESA dose was associated with higher FGF23 levels measured by both intact and C-terminal assays. Higher C-terminal FGF23 was also associated with higher ERI, lower hemoglobin, and higher endogenous EPO, but no such associations were observed for intact FGF23 levels.
Conclusions. Both intact and C-terminal FGF23 showed similar associations with ESA dose, but they showed different patterns of association with other parameters related to anemia. Further research is needed to elucidate the mechanisms underlying these different associations.
DOI: 10.6084/m9.figshare.28181405.v4
title: Supplementary Material for: Fibroblast growth factor 23, endogenous erythropoietin, erythropoiesis-stimulating agents, and erythropoietin resistance in hemodialysis patients

description: Introduction. Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO has been shown to stimulate FGF23 production. However, little is known about the relationships between FGF23, erythropoiesis-stimulating agent (ESA) treatment, ESA resistance, and endogenous EPO in hemodialysis patients.
Methods. We analyzed cross-sectional data from a cohort of 654 maintenance hemodialysis patients. We examined the associations of intact or C-terminal FGF23 with ESA treatment, ESA resistance index (ERI), hemoglobin, C-reactive protein, and endogenous EPO levels using linear regression models. EPO was measured only in patients not receiving ESAs.
Results. A total of 458 patients (70%) were treated with ESAs. The median EPO concentration in non-ESA users was 7.8 (interquartile range, 5.3-14.4) mIU/mL. The median levels of intact and C-terminal FGF23 were 1598 (interquartile range, 548-4586) pg/mL and 38.7 (interquartile range, 14.0-127.6) pmol/L, respectively, in non-ESA users and 1955 (interquartile range, 573-5264) pg/mL and 41.4 (interquartile range, 13.9-116.8) pmol/L, respectively, in ESA users. After adjustment for potential confounders, higher ESA dose was associated with higher FGF23 levels measured by both intact and C-terminal assays. Higher C-terminal FGF23 was also associated with higher ERI, lower hemoglobin, and higher endogenous EPO, but no such associations were observed for intact FGF23 levels.
Conclusions. Both intact and C-terminal FGF23 showed similar associations with ESA dose, but they showed different patterns of association with other parameters related to anemia. Further research is needed to elucidate the mechanisms underlying these different associations.
DOI: 10.6084/m9.figshare.28181405.v5
title: Supplementary Material for: Fibroblast growth factor 23, endogenous erythropoietin, erythropoiesis-stimulating agents, and erythropoietin resistance in hemodialysis patients

description: Introduction. Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO has been shown to stimulate FGF23 production. However, little is known about the relationships between FGF23, erythropoiesis-stimulating agent (ESA) treatment, ESA resistance, and endogenous EPO in hemodialysis patients.
Methods. We analyzed cross-sectional data from a cohort of 654 maintenance hemodialysis patients. We examined the associations of intact or C-terminal FGF23 with ESA treatment, ESA resistance index (ERI), hemoglobin, C-reactive protein, and endogenous EPO levels using linear regression models. EPO was measured only in patients not receiving ESAs.
Results. A total of 458 patients (70%) were treated with ESAs. The median EPO concentration in non-ESA users was 7.8 (interquartile range, 5.3-14.4) mIU/mL. The median levels of intact and C-terminal FGF23 were 1598 (interquartile range, 548-4586) pg/mL and 38.7 (interquartile range, 14.0-127.6) pmol/L, respectively, in non-ESA users and 1955 (interquartile range, 573-5264) pg/mL and 41.4 (interquartile range, 13.9-116.8) pmol/L, respectively, in ESA users. After adjustment for potential confounders, higher ESA dose was associated with higher FGF23 levels measured by both intact and C-terminal assays. Higher C-terminal FGF23 was also associated with higher ERI, lower hemoglobin, and higher endogenous EPO, but no such associations were observed for intact FGF23 levels.
Conclusions. Both intact and C-terminal FGF23 showed similar associations with ESA dose, but they showed different patterns of association with other parameters related to anemia. Further research is needed to elucidate the mechanisms underlying these different associations.
DOI: 10.6084/m9.figshare.28181405
title: Supplementary Material for: Fibroblast growth factor 23, endogenous erythropoietin, erythropoiesis-stimulating agents, and erythropoietin resistance in hemodialysis patients

description: Introduction. Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO has been shown to stimulate FGF23 production. However, little is known about the relationships between FGF23, erythropoiesis-stimulating agent (ESA) treatment, ESA resistance, and endogenous EPO in hemodialysis patients.
Methods. We analyzed cross-sectional data from a cohort of 654 maintenance hemodialysis patients. We examined the associations of intact or C-terminal FGF23 with ESA treatment, ESA resistance index (ERI), hemoglobin, C-reactive protein, and endogenous EPO levels using linear regression models. EPO was measured only in patients not receiving ESAs.
Results. A total of 458 patients (70%) were treated with ESAs. The median EPO concentration in non-ESA users was 7.8 (interquartile range, 5.3-14.4) mIU/mL. The median levels of intact and C-terminal FGF23 were 1598 (interquartile range, 548-4586) pg/mL and 38.7 (interquartile range, 14.0-127.6) pmol/L, respectively, in non-ESA users and 1955 (interquartile range, 573-5264) pg/mL and 41.4 (interquartile range, 13.9-116.8) pmol/L, respectively, in ESA users. After adjustment for potential confounders, higher ESA dose was associated with higher FGF23 levels measured by both intact and C-terminal assays. Higher C-terminal FGF23 was also associated with higher ERI, lower hemoglobin, and higher endogenous EPO, but no such associations were observed for intact FGF23 levels.
Conclusions. Both intact and C-terminal FGF23 showed similar associations with ESA dose, but they showed different patterns of association with other parameters related to anemia. Further research is needed to elucidate the mechanisms underlying these different associations.
DOI: 10.6084/m9.figshare.28181405.v7
title: Supplementary Material for: Fibroblast growth factor 23, endogenous erythropoietin, erythropoiesis-stimulating agents, and erythropoietin resistance in hemodialysis patients

description: Introduction. Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO has been shown to stimulate FGF23 production. However, little is known about the relationships between FGF23, erythropoiesis-stimulating agent (ESA) treatment, ESA resistance, and endogenous EPO in hemodialysis patients.
Methods. We analyzed cross-sectional data from a cohort of 654 maintenance hemodialysis patients. We examined the associations of intact or C-terminal FGF23 with ESA treatment, ESA resistance index (ERI), hemoglobin, C-reactive protein, and endogenous EPO levels using linear regression models. EPO was measured only in patients not receiving ESAs.
Results. A total of 458 patients (70%) were treated with ESAs. The median EPO concentration in non-ESA users was 7.8 (interquartile range, 5.3-14.4) mIU/mL. The median levels of intact and C-terminal FGF23 were 1598 (interquartile range, 548-4586) pg/mL and 38.7 (interquartile range, 14.0-127.6) pmol/L, respectively, in non-ESA users and 1955 (interquartile range, 573-5264) pg/mL and 41.4 (interquartile range, 13.9-116.8) pmol/L, respectively, in ESA users. After adjustment for potential confounders, higher ESA dose was associated with higher FGF23 levels measured by both intact and C-terminal assays. Higher C-terminal FGF23 was also associated with higher ERI, lower hemoglobin, and higher endogenous EPO, but no such associations were observed for intact FGF23 levels.
Conclusions. Both intact and C-terminal FGF23 showed similar associations with ESA dose, but they showed different patterns of association with other parameters related to anemia. Further research is needed to elucidate the mechanisms underlying these different associations.